Cargando…
Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288429/ http://dx.doi.org/10.1186/2051-1426-2-S3-P125 |
| _version_ | 1782351971234086912 |
|---|---|
| author | Shafren, Darren Quah, Min Wong, Yvonne Andtbacka, Robert HI Kaufman, Howard L Au, Gough G |
| author_facet | Shafren, Darren Quah, Min Wong, Yvonne Andtbacka, Robert HI Kaufman, Howard L Au, Gough G |
| author_sort | Shafren, Darren |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288429 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42884292015-01-15 Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model Shafren, Darren Quah, Min Wong, Yvonne Andtbacka, Robert HI Kaufman, Howard L Au, Gough G J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288429/ http://dx.doi.org/10.1186/2051-1426-2-S3-P125 Text en Copyright © 2014 Shafren et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Shafren, Darren Quah, Min Wong, Yvonne Andtbacka, Robert HI Kaufman, Howard L Au, Gough G Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model |
| title | Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model |
| title_full | Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model |
| title_fullStr | Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model |
| title_full_unstemmed | Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model |
| title_short | Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model |
| title_sort | combination of a novel oncolytic immunotherapeutic agent, cavatak (coxsackievirus a21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288429/ http://dx.doi.org/10.1186/2051-1426-2-S3-P125 |
| work_keys_str_mv | AT shafrendarren combinationofanoveloncolyticimmunotherapeuticagentcavatakcoxsackievirusa21andimmunecheckpointblockadesignificantlyreducestumorgrowthandimprovessurvivalinanimmunecompetentmousemelanomamodel AT quahmin combinationofanoveloncolyticimmunotherapeuticagentcavatakcoxsackievirusa21andimmunecheckpointblockadesignificantlyreducestumorgrowthandimprovessurvivalinanimmunecompetentmousemelanomamodel AT wongyvonne combinationofanoveloncolyticimmunotherapeuticagentcavatakcoxsackievirusa21andimmunecheckpointblockadesignificantlyreducestumorgrowthandimprovessurvivalinanimmunecompetentmousemelanomamodel AT andtbackaroberthi combinationofanoveloncolyticimmunotherapeuticagentcavatakcoxsackievirusa21andimmunecheckpointblockadesignificantlyreducestumorgrowthandimprovessurvivalinanimmunecompetentmousemelanomamodel AT kaufmanhowardl combinationofanoveloncolyticimmunotherapeuticagentcavatakcoxsackievirusa21andimmunecheckpointblockadesignificantlyreducestumorgrowthandimprovessurvivalinanimmunecompetentmousemelanomamodel AT augoughg combinationofanoveloncolyticimmunotherapeuticagentcavatakcoxsackievirusa21andimmunecheckpointblockadesignificantlyreducestumorgrowthandimprovessurvivalinanimmunecompetentmousemelanomamodel |